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“Two chambers hath the heart.
There dwelling,
Live Joy and Pain apart.”
-Hermann Neumann, German poet, 1808-1875
In honour of my parents Ann-Sofi Ahlbom and Anders Fredriksson, for 
teaching me how to strive through the pain of tired eyes staring at text-
books during late nights before an exam and the joys of deciphering the 




Atrial fibrillation (AF) is the most common clinically relevant arrhythmia. It 
is diagnosed using an electrocardiogram (ECG) and defined as an irregular 
heart rhythm without p-waves lasting for at least 30 seconds. This 30-sec-
ond time criterion is based solely on expert consensus. AF is associated 
with a five-fold increase in stroke risk but with use of stroke preventive oral 
anticoagulation treatment, the risk can be reduced by at least two thirds. 
Connections between supraventricular activity, AF and stroke have been 
identified in register studies. Still, there are no studies evaluating the risks 
associated with episodes of AF-like activity with duration shorter than 30 
seconds, termed micro-AF. One can assume that micro-AF is associated 
with AF, but there are no guidelines for clinicians on how to investigate 
or treat individuals with these findings. 
The aims of this thesis are: 1) to evaluate if individuals with micro-AF 
have a higher risk of subsequent AF and thus would benefit from extended 
screening and follow-up; 2) to study the prevalence of micro-AF in an elderly 
population; 3) to postulate the time span from micro-AF to AF; 4) to assess 
if micro-AF burden predict development of AF; 5) to identify which inves-
tigation is the most suitable to detect AF in an elderly, high-risk popula-
tion by comparing intermittent ECG and continuous event-recording; 6) 
finally, the thesis aspires to gain a larger perspective by comparing the 
risks associated with micro-AF to the risk increase in individuals with 
other types of excessive supraventricular activity.
METHODS AND RESULTS
The participants in study I were identified from STROKESTOP I, a popu-
lation-based mass-screening study for AF. In STROKESTOP I individuals 
aged 75- and 76-years recorded intermittent ECGs for 30 seconds, twice 
daily for two weeks. Participants free from AF but in whom micro-AF was 
detected were followed-up. In study I micro-AF was defined as abrupt 
onset episodes of irregular heart rhythm, ≥4 consecutive supraventricular 
beats and absence of p-waves lasting for less than 30 seconds. Participants 
free from both micro-AF and AF acted as a control group. After 2.3 years 
both groups were invited to repeat AF screening using intermittent ECG 
for 30 seconds twice daily in parallel with continuous event-recording for 
two weeks. AF was found in 50% (n=27/54) of participants in the micro-
AF group compared to 10% (n=5/48) in the control group, p<0.001. One 
hundred percent of the AF cases detected during repeat screening were 
found by the continuous event-recorder and of those, intermittent ECG 
detected 40%. 
In study II, participants were identified from the STROKESTOP II study – 
similarly to STROKESTOP I, a mass-screening study for AF. In contrast only 
participants with N-terminal pro b-type natriuretic peptides (NT-proBNP) 
levels ≥125 ng/L were asked to perform intermittent ECG four times daily for 
two weeks. Participants free from AF but with micro-AF during intermittent 
recordings were invited to additional extended screening using continu-
ous event-recording for two weeks. A tachycardia criterion was added to 
the micro-AF definition, and the duration was prolonged to ≥5 consecutive 
beats (the same definition was also used in study IV). A control group was 
screened using both ECG modalities simultaneously in STROKESTOP II. 
Continuous event-recording detected AF in 13% (n=26/196) in the micro-
AF group and 3% (n=7/250) in the control group, p <0.001. 
The group performing intermittent ECGs and continuous event-recording 
in parallel during STROKESTOP II were also invited to participate in study 
III. The participants were asked to fill out a questionnaire comparing 
ease of use and compliance to the two ECG modalities; the intermittent 
ECG, a Zenicor II device and the continuous event-recording, an R-Test 4 
device from Novacor. Continuous event-recording detected new AF in 6% 
(n=15/269) and intermittent ECG in 2% (n=5/269), p=0.002. Both devices 
were well tolerated, but intermittent ECG was graded “very easy to use” 
whereas continuous event-recording was graded “easy to use”, p<0.001. 
Study I included parts of the participants with micro-AF in STROKESTOP I. 
In study IV an automated algorithm was used to identify all participants with 
micro-AF and other supraventricular arrhythmias in the STROKESTOP I 
database. All ECGs identified by the algorithm were also manually assessed. 
Participants were followed up using three-year data from National Swedish 
Health registers. Supraventricular tachycardias were associated with an 
increased risk of AF compared to excessive supraventricular ectopic beats. 
Participants with supraventricular tachycardias with AF characteristics, 
micro-AF, n= 97 (1,6%), were shown to have a higher risk of AF than par-
ticipants with other supraventricular arrhythmias (hazard ratio 4,3; 95% 
confidence interval 2,7-6,8). They also had an increased risk of death 
(hazard ratio 2,0; 95% confidence interval 1,1-3,8).
CONCLUSION
Extensive supraventricular ectopy, including frequent isolated supraven-
tricular ectopic beats and supraventricular tachycardias, is common 
and associated with AF development in elderly people. Individuals with 
supraventricular tachycardias with AF characteristics – termed micro-AF – 
showed the highest risk of a future AF as well as an increased risk of death. 
Micro-AF also seems to be associated with an increased risk of already 
existing undetected AF. The risk of having AF detected by  screening seems 
to increase with time in individuals with micro-AF, indicating a  possibly 
progressive disease in the atria. We found no evidence that micro-AF 
burden affects AF development. Extended and repeat screening could be 
recommended for the elderly population with micro-AF as detection of AF 
in the majority of cases would lead to initiation of stroke preventive oral 
anticoagulant treatment. Intermittent ECG is well tolerated as a screen-
ing method in an elderly population, but continuous event-recording for 
two weeks detects three-times as many new cases of AF and is therefore 
a preferable screening method. 
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LIST OF ABBREVIATIONS 
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Micro-AF Episode of atrial fibrillation-like activity lasting for 
<30 seconds
PPM Permanent pacemaker
SVEB Supraventricular Ectopic Beat
SVT Supraventricular Tachycardia
TIA Transient Ischaemic Attack
PREFACE
The guidelines from the European Society of Cardiology define atrial fibril-
lation as an irregular heart rhythm with absence of p-waves lasting for at 
least 30 seconds. I recall a classmate raising her hand during a lecture 
at university asking why an arrhythmia had to last for 30 seconds to be 
classified as atrial fibrillation. We were told that changes in the movement 
patterns of the atrium during a longer time period lead to stasis and risk 
of thrombus formation. What was never made clear to us though was that 
the choice of a 30-second duration for the definition was completely arbi-
trary. During my last semester of medical studies, I came in to contact 
with Emma Svennberg, who at the time was working with STROKESTOP 
I, a mass-screening study for atrial fibrillation in 75- and 76-year olds 
using intermittent ECG. She had noticed that many of the participants 
had episodes that seemed similar to atrial fibrillation, but with a duration 
shorter than 30 seconds. They had no indication for oral anticoagulation, 
but would they benefit from follow-up? 
This is where I entered the stage. I was just starting my PhD studies and 
was already focused on micro-atrial fibrillation. As I began pouring over 
the literature, I realized that an association between supraventricular 
ectopic beats, supraventricular tachycardia and atrial fibrillation had 
been seen in several register studies. Individuals with these arrhythmias 
were also shown to have an increased risk of stroke. Still there were no 
guidelines regarding follow-up and treatment of this group. The absence of 
guidelines could be at least partly explained by the long follow-up periods 
before atrial fibrillation was diagnosed in the register studies and the fact 
that the increased risk of stroke could be due to undiagnosed atrial fibril-
lation. I began asking myself if atrial thrombus formation could appear 
during short arrhythmia episodes, as I knew that atrial fibrillation patients 
had an increased risk of stroke even during long arrhythmia free periods. 
When I participated in a conference of the European Society of Cardiology 
in Rome during 2016, I got the chance to talk to some senior colleagues 
during a coffee break. That was when my eyes were opened to the theory 
of atrial myopathy that can both be prothrombotic in itself but also cause 
disturbances in the electrical signalling of the heart. Shorter arrhythmia 
episodes, like micro-atrial fibrillation, could be potential signs of atrial 
myopathy and therefore associated with an increased risk of stroke. 
This thesis is an effort to establish the risks and clinical implications of 
short episodes of atrial fibrillation-like activity, i.e. micro-atrial fibrillation.
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1 INTRODUCTION
1.1 Prevalence of atrial fibrillation 
Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia 
in the adult population. The prevalence of clinically diagnosed AF is approxi-
mately 3% in the population >18 years of age (1-3). The prevalence increases 
with age and is slightly higher in men than in women per age strata (1, 4). 
By 2010 about 30% of the total population in the European Union was ≥55 
years old, a number expected to increase to 41.1 % by 2060 (5). This demo-
graphic shift in combination with a higher prevalence of AF in older popula-
tions give an estimated AF prevalence set to double within a 50-year period 
(5, 6). The expected lifetime risk of developing AF for middle aged men and 
women living in Europe and the U.S. today is approximately 25% (3, 4, 7). 
The true prevalence of AF is probably underestimated in other parts of the 
world due to lack of epidemiological data, and this underestimation may 
also be true in Europe and the U.S. (8). AF can be asymptomatic and par-
oxysmal and could therefore remain undiagnosed. By screening a popula-
tion of 75- and 76-year olds in Sweden, the AF prevalence increased from 
9.3% before to 12.3% after screening (9). 
Hence, an increase in AF prevalence may be both due to better detection 
of AF in asymptomatic patients (9-11), an ageing population and changes 
in AF-related co-morbidities (12). 
1.2 Risk factors for atrial fibrillation
AF is commonly a multifactorial disease, and a single predisposing condi-
tion can be difficult to ascertain. 
The European Society of Cardiology (ESC) has summarised the risk factors 
for AF. Early-onset AF is believed to have a strong genetic component. About 
one third of patients diagnosed with AF carry genetic variants predisposing 
for AF, although the increased risk of developing AF in these individuals is 
mild to moderate. In addition, simply being male is associated with AF. The 
diseases associated with an increased risk of developing AF are; diabetes 
mellitus, hypertension, valvular disease, heart failure, myocardial infarc-
tion, obstructive sleep apnoea, chronic obstructive pulmonary disease, 
obesity, renal failure and thyroid disease, (see figure 1). Also, lifestyle fac-
tors such as smoking, high alcohol consumption, but also both physical 
inactivity and extensive physical activity predispose for AF development 
(13, 14). Except from age, sex and genetics, many of these risk factors are 
potentially reversible. Hence, primary and secondary prevention for AF 





















Figure 1. Risk factors for atrial fibrillation
1.3 Diagnostic criteria for atrial fibrillation 
The diagnostic criteria for AF according to ESC guidelines include the fol-
lowing ECG patterns: absolute irregular rate-to-rate intervals, absence 
of normal p-waves and a duration of at least 30 seconds. The 30-second 
rule is due to accepted convention. The diagnosis of AF is independent of 
symptomatology (13). 
During AF, atrial activity might be seen on the ECG, but the atrial com-
plexes have a different configuration and a there is a variance in distance 
between the different atrial complexes. The atrial frequency during AF is 
>300 per minute (15) and cannot be assessed by a standard ECG recording.
1.4 Classification of atrial fibrillation 
Based on presentation, duration and type of termination AF is classified into 
five different groups: first diagnosed, paroxysmal, persistent, long-standing 
persistent and permanent (13). AF commonly progresses from short and 
infrequent episodes to more permanent forms over time, but the progression 
to permanent forms of AF is slower in young and healthy individuals (16).
• First diagnosed AF – when AF is first diagnosed in a patient with 
no prior diagnosis of AF. 
• Paroxysmal AF – when AF terminates within seven days.
• Persistent AF – when an episode lasts for more than 7 days or if 
cardioversion is needed to restore sinus rhythm after ≥7 days.
• Long-standing persistent AF – when AF lasts for more than one 
year, but the aim is to regain sinus rhythm. 
• Permanent AF – when the arrhythmia is life-lasting and is accepted 
by the physician and patient, who receives no rhythm control 
treatment (13).        
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1.5 Pathophysiology of atrial fibrillation
During normal sinus rhythm, the sinus node starts the electric signalling 
leading to progressive activation of the whole myocardium. The initiation 
of AF instead starts in one or several ectopic foci. The signalling from the 
ectopic focus, often located near the pulmonary veins, is fast and irregular 
(17). The pace is slowed down in the atrioventricular node, but still causes 
irregular heart rhythm and often tachycardia (18)(see figure 2). 
Figure 2. An over-view of electrical signalling during A) Sinus rhythm and B) 
Atrial fibrillation 
Initially during tachycardia an excess of calcium is transported into the 
myocytes. This in turn causes an increased calcium release from the sarco-
plasmic reticulum in the myocyte, leading to even higher levels of calcium 
in the myocytes (19, 20). The calcium imbalance is believed to cause elec-
trical remodelling that contributes to maintaining the arrhythmia through 
rate dependant shortening of wavelength by reduced atrial repolarization 
period and reduced refractory phase (21-24). Parts of the electrical remod-
elling are reversible but can persist for a few days after conversion to sinus 
rhythm, which in turn facilitates recurrence of AF (22, 25). 
The calcium overload combined with metabolic stress leads to increase in 
myocyte size and myolysis (26). The myocyte changes could possibly cause 
inflammation resulting in a common pathophysiological pathway: atrial fibrosis 
(27). There are many other mechanisms also causing atrial fibrosis, for exam-
ple hypertension, heart failure or high age. Atrial fibrosis isolates myocytes, 
creating a milieu where re-entry arrhythmia, like AF, can exist (26, 28, 29). 
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After some time of tachycardia the calcium deposits in the sarcoplasmic 
reticulum are reduced, leading to decreased contractility in the atria which 
eventually may also lead to atrial dilatation (30). Atrial enlargement due 
to loss of contractility is associated with recurrence of AF (29).
The contractility of the left atrium decreases during episodes of AF. This 
change could lead to stasis and thrombus formation in the left atrial 
appendage (see figure 3). 
Figure 3. Thrombus formation in the left atrial appendage.
Ischaemic stroke is commonly caused by thrombus embolization from the 
left atrium to cerebral arteries. However, in patients with high CHA2DS2VASc 
scores (used for stroke risk stratification) and stable vascular atherosclerosis, 
OAC treatment has been shown to lead to significant reduction of ischaemic 
stroke risk even in sinus rhythm (31), making other mechanisms contributing 
to thrombus formation likely. Markers of atrial dysfunction have been shown 
to be associated with an increased risk of cryptogenic or embolic stroke, but 
not cerebral small vessel occlusions. The increased risk of only cryptogenic 
or embolic stroke indicates an atrial origin of the thrombus rather than it 
being caused by general vascular disease (32). One example of underlying 
mechanisms is extensive atrial fibrosis (33), which could possibly both pre-
dispose for AF and contribute to increased stroke risk even in the absence of 
AF, by atrial prothrombotic changes. This suggests that all atrial arrhythmia, 
potentially even micro-AF, may be a sign of atrial cardiomyopathy and could 
thereby be independently associated with an increased stroke risk. 
1.6 Risks related to atrial fibrillation  
Stroke is the third leading cause of death in Sweden (34). At least 20% of 
all strokes are directly attributable to AF (35). In total, AF is diagnosed 
in 31-38% of patients with stroke (35, 36). The attributable risk of AF for 
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stroke increases with age, in contrast to other risk factors for stroke (15) 
and is diagnosed in at least 50% of stroke patients aged ≥80 years (36). 
Ischaemic strokes related to AF are more severe compared to other ischaemic 
strokes and also carry increased stroke morbidity and mortality (37, 38). 
Oral anticoagulant treatment (OAC) in AF patients is associated with at 
least a 64% decrease in stroke risk (39). CHA2DS2-VASc score is used for 















Figure 4. The CHA2DS2-VASc score used for assessing the stroke risk in AF 
patients. TIA indicates transient ischemic attack. Vascular disease includes for 
example peripheral artery disease and myocardial infarction. 
According to current ESC guidelines, OAC treatment is recommended in 
all women with CHA2DS2-VASc score ≥3 and all men with ≥ 2. The benefit 
of OAC therapy should be weighed against the risk of bleeding; however, 
many risk factors for haemorrhagic stroke are also risk factors for ischae-
mic stroke, and most AF patients benefit from OAC treatment (13). 
Not only is AF related to ischaemic stroke, it is also associated with sev-
eral other co-morbidities and increased mortality. AF is associated with 
an increased risk of dementia, independent of clinically diagnosed stroke 
(40). A recent register-based study also suggests that OAC treatment is 
associated with a decreased risk of dementia in AF patients (41). 
Individuals with AF have a 22% 10-year incidence of new onset heart fail-
ure. The risk factors for AF and heart failure are similar (42). AF is also 
associated with doubled mortality in both men and women after adjusting 
for potential confounders (43). 
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1.7 Population screening for Atrial fibrillation  
As AF can be asymptomatic and still associated with an increased risk of 
stroke, it is important to diagnose AF early to prevent this risk (44, 45). 
AF screening can potentially facilitate early detection of AF. 
Screening can be opportunistic or systematic. Opportunistic screening 
refers to screening of individuals who receive health care for other reasons. 
Systematic screening refers to screening of a population invited especially 
for that purpose, for instance mammography screening for breast cancer 
in women above a certain age. 
In the SAFE study, a multicentre randomised controlled trial among indi-
viduals aged ≥ 65-year old, detection rates in primary care centres using 
either opportunistic or systematic AF screening were compared with 
 detection rates in a control group. In this study, participants in the sys-
tematic screening group were invited to attend a screening clinic to have 
a 12 lead ECG taken. In the opportunistic screening group, an ECG was 
taken if irregularity was found by pulse palpation during a routine primary 
care visit. The AF incidences per year were: 1.04% in the control group, 
1.64% in the opportunistic screening group and 1.62% in the systemic 
screening group. The opportunistic screening programme was shown to 
be the least expensive and easiest alternative, carrying a 60% probability 
of being cost-effective (46). 
In a meta-analysis it was shown that population screening using a single 
time point ECG in individuals ≥65 years old yielded an overall AF preva-
lence of 4.4% and a prevalence of new and previously undiagnosed AF of 
1.4% (47).  
Based on the studies mentioned above the current ESC guidelines recom-
mend opportunistic screening in populations aged >65 years, either by 
pulse palpation or ECG rhythm strip (13). Using this screening method, 
individuals with more permanent forms of AF can be identified. 
By systematic screening using a handheld one-lead device performing inter-
mittent 30-second ECGs twice daily for two weeks in the STROKESTOP I 
study, the AF prevalence in an unselected population of 75- and 76-year-
olds increased by 3 percentage points, from 9.3% to 12.3%. Only a small 
proportion of the screened population had AF detected on index-ECG, 0.5% 
(9). In a study with similar design and population, but with at least one more 
stroke risk factor apart from age, the known AF prevalence increased by 7.4 
percentage points after screening (48). There is variance in the AF preva-
lence between primary preventive systematic screening studies, depending 





































Repeated ECG for 2 weeks,
mean CHA2DS2-VASc =3
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Twice weekly ECG for 1 year. 
Mean CHA2DS2-VASc =3
Engdahl
Repeated ECG for 2 weeks,
mean CHA2DS2-VASc =2.5
ASSERT-II
1.35 year  follow-up 
with ICM, mean
CHA2DS2-VASc =4.1
Figure 5. Prevalence of asymptomatic atrial fibrillation by screening method and 
stroke risk score. Reprinted courtesy of European Heart Journal: 2020;41(10) 
Oxford University Press © Colors and font re-made for use in this thesis. CRT-D 
indicates Cardiac resynchronization therapy with defibrillator. ICD indicates 
implantable cardioverter defibrillator. PPM indicates permanent pacemaker. 
According to ESC guidelines systematic screening may be considered in 
individuals >75-years old or with high risk of stroke (13).
1.8 Atrial fibrillation screening in stroke patients 
In patients with prior stroke or TIA and without known AF extended ECG 
monitoring in addition to standard follow-up after such events (often 24 
hours ECG monitoring) have been shown to significantly increase the AF 
detection. In one study the prevalence previously unknown AF increased 
from 2.6% after 24 hours ECG monitoring to 4.3% after 72 hours ECG 
monitoring (49). In another study, seven days of continuous event-recording 
detected AF in 5.7% of participants without AF found on neither 12 lead 
ECG or 24 hour Holter ECG. (50). In a study using long-term monitor-
ing with an insertable cardiac monitor for 12 months, the AF prevalence 
increased by 10.4 percentage points (10).  
In patients >65-years old suffering from TIA or ischaemic stroke and not 
diagnosed with AF, a 30-second intermittent recording twice daily for 30 
days was compared to five days continuous ECG. Intermittent recording 
detected AF in 21% of participants compared to 18% by continuous ECG. 
Only 11% were diagnosed using both methods (51). 
Previous TIA or stroke has in addition to age been shown to be the most 
important risk factors for new stroke in AF patients (52). Accordingly ESC 
guidelines recommend screening for AF by an ECG rhythm strip followed by 
at least 72 hours ECG monitoring in patients with TIA or ischaemic stroke. 
Long-term non-invasive loop-recorders or implantable loop-recorders may 
also be used in patients with ischaemic stroke (13).
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1.9 Different screening devices 
There are many different screening methods for AF detection. Commonly 
used screening methods are summarised in a report from the AF-SCREEN 
International Collaboration (53). Pulse palpation, oscillometric blood pres-
sure monitors with AF detection function and photoplethysmography, can 
all identify individuals with irregular pulse, but an ECG is recommended 
for AF diagnosis. There are many different handheld devices used for single 
time-point screening or prolonged intermittent screening. The hand-held 
devices are user-friendly and have a higher sensitivity and specificity for 
AF detection than pulse-based screening methods (54). Long periods of 
internal and external continuous monitoring might detect paroxysmal AF 
more effectively than repeated intermittent screening with a hand-held 
device. Using continuous external ECG recording introduces potential 
problems with compliance, often due to skin irritation from electrodes and 
patches (55). Wristwatches with ECG recording capacity have now also 
become available for AF-screening (56). 
The two devices used in this thesis have both been validated previously. 
The hand-held intermittent ECG from Zenicor has been validated for AF 
detection compared to 12-lead ECG and has a 96% sensitivity and a 92% 
specificity (57). Intermittent ECG recordings have been further studied in a 
cohort of patients with known paroxysmal AF. AF episodes were detected in 
82% using intermittent recordings 10 seconds twice daily during a 30-days 
period compared to 32% detected by the 24-hour continuous recording 
(58). In a validation study, the algorithm of the continuous event-recorder, 
R-test 4 from Novacor, had a 92% sensitivity and 87% specificity for AF 
detection in comparison to continuous ECG (59).
1.10 Stroke risk, AF classification and AF symptoms
Common symptoms related to AF are dyspnoea, chest discomfort, palpita-
tions, fatigue, dizziness and syncope (60). About one third of AF patients 
are thought to be asymptomatic (61). An association between asymptomatic 
AF and higher age, as well as more co-morbidities and permanent AF has 
been seen. Regardless of symptoms patients with AF have an increased 
risk of stroke and seem to have an increased risk of death (44, 45). A recent 
systematic review found no difference in stroke risk depending on presence 
of symptoms and concluded that symptomatic status should not be taken 
into account in determination of treatment approach (62). 
Participants in a cohort study with incidentally diagnosed AF were found 
to have a two-fold increase in incidence of stroke compared to individuals 
with no AF. OAC treatment reduced stroke risk by >60% and mortality by 
>40% in this group. Half the individuals with incidentally diagnosed AF 
were already initiated on OAC treatment, making it likely that the stroke 
risk was underestimated (63). One might hypothesise that the risks iden-
tified in this study may serve as an indicator of the risks associated with 
screening-detected AF.
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There is contrasting evidence also with regards to the risk of stroke depend-
ing on type of AF. Stroke rates in individuals with permanent AF have in 
several studies been shown to be equal to paroxysmal AF after adjust-
ment for stroke risk factors (39, 64, 65). In contrast, other studies have 
shown that persistent and permanent forms of AF are associated with an 
increased risk of stroke compared to paroxysmal AF, even after adjusting 
for CHA2DS2-VASc score (66-68). 
The ESC guidelines do not endorse taking AF type, AF burden or symp-
toms into account in stroke risk assessment. Evaluation of stroke risk in 
AF patients should only be based on CHA2DS2-VASc score. ECG verified 
screening-detected AF is treated the same as clinically diagnosed AF (13).
1.11 Prevalence of supraventricular ectopy
A supraventricular ectopic beat (SVEB) is a premature complex arising from 
the atria or the atrioventricular junction, instead of from the sinus node, which 
normally initiates cardiac activation. SVEBs can be unifocal or multifocal. 
They can appear randomly or with regular intervals, resulting in bigeminal 
or trigeminal rhythm. Increased automaticity is the most common under-
lying mechanism of SVEBs (69). Episodes of ≥3 consecutive SVEBs with a 
rate  >100 beats per minute are called supraventricular tachycardias (SVTs). 
One study using 24-hour Holter monitoring evaluated the SVEB burden 
in individuals with normal cardiac catheterization in the United States Air 
Force Aeromedical Consultation Service. No SVEBs were found in 11.9%, 
≤ 0.1% SVEBs were found in 72.9% and >0.1% SVEBs were found in 5.2% 
of participants. SVTs with a duration of 3-10 beats was found in 4.3% of 
participants (70). Another study focused on individuals aged ≥75 years 
without acute medical conditions. It found that 21% of these individuals 
had SVEBs seen during 24-hour ECG monitoring and 1% had SVTs (71). 
In a study among healthy 60-85 year olds, SVEBs were found in 88% and 
SVTs were found in 13% of the participants 24-hour ECGs (72). Inspection 
of recordings from patients in all ages who underwent examination after 
syncope at The Medical Centre Hospital of Vermont displayed presence of 
SVEBs during 24-hour ECG monitoring ranging from 15% below age 30 
years to 58% in patients ≥70 years. SVTs were found in 1% of participants 
<30 years old and in up to 40% in participants aged ≥ 70 years (73).
1.12 Relationship between supraventricular ectopy, 
AF and stroke  
Several studies have shown that supraventricular ectopy - both isolated 
SVEBs and SVTs - during 24 hours ECG monitoring is associated with an 
increased risk of AF and stroke (74-76). Similar results were seen when 
SVEBs were detected during single time-point ECG (77, 78). Important 
studies of SVEBs and SVTs are listed (see table 1) and some of these stud-


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In a study by Binici et al. healthy men and women aged 55-75 years old 
were examined with 48-hour Holter recordings and followed up in registers. 
A three-fold risk of clinically diagnosed AF and a >60% increase in risk of 
stroke and death was seen in individuals with ≥ 20 SVEBs in runs or ≥ 30 
SVEBs/hour after a mean follow up of 6.3 years. The >30 SVEBs/hour 
division represent the top tenth percentile SVEB frequency in the popula-
tion studied (79). Larsen et al. concluded from the same study material 
that participants with these findings and CHA2DS2-VASc -score ≥ 2 have 
a stroke incidence comparable to individuals with AF at 2.4 % per year. 
The stroke risk was increased even after exclusion of individuals diagnosed 
with AF prior to stroke from the analysis (82). Frequency of SVEBs, as 
well as length of a SVEB runs were linearly associated with incidence of 
AF. Participants with SVEB runs of 5-10 beats had an annual risk for AF 
of approximately 0.7 %, the risk was increased five-fold compared to the 
risk in those without SVEB runs (79). 
In a similar study by Marinheiro et al., individuals with a mean age slightly 
above 70 years had undergone 24-hour ECG monitoring. The ECGs were 
assessed for frequency of SVEBs. Only in the group with the top fifth per-
centile SVEB frequency, >97 per hour, frequent SVEBs were independently 
associated with an increased stroke risk of 3,5% per year (83). 
In another study by Johnson et al., individuals with a mean age of 65 
years who had undergone 24-hour Holter ECG were followed in registers 
for a mean of 10.3 years. Their 24-hour Holter ECGs were scrutinized for 
number of SVEBs per hour, number of SVTs per hour, maximum heart 
rate during SVT, duration of SVTs and excessive supraventricular activity, 
meaning ≥30 per hour or ≥20 SVEBs in a run. Both number of SVEBs/
hour, SVTs/hour and excessive supraventricular activity did indepen-
dently predict future AF. The SVT duration and heart rate did not predict 
future AF (74).
In patients with AF symptoms, high burden of SVEBs was in study by 
Chong et al. associated with a three-fold increase in risk of stroke com-
pared to a low burden of SVEBs, with the difference remaining significant 
even after adjusting for potential confounders (80). 
In a study of stroke patients by Kochhauser et al., a high burden of SVEBs 
was associated with a four-fold increase in risk of future AF and high a 
burden of SVTs was associated with a seven-fold increase in risk of future 
AF (81). 
Johnson et al. found that there was a stronger association between short 
irregular SVTs without p-waves and AF, compared short regular SVTs 
without p-waves, that seemed less likely to progress into AF (84).
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Although all these studies suggest an increased risk of AF and/or stroke 
the endpoints have all been from registries. In particular for asympto-
matic AF there might be risk of underdiagnosis. In addition, there are no 
published studies assessing the value of OAC treatment in patients with 
excessive supraventricular activity. 
1.13 Stroke risk in patients with device detected 
atrial high rate episodes 
In patients with an implanted pacemaker or defibrillator equipped with an 
atrial lead, the device can automatically detect and record atrial tachyar-
rhythmia. The data recorded have been used in several studies to evaluate 
if these atrial high rate episodes (AHRE) are associated with AF and stroke. 
The definition of AHRE varies in different studies, but a common definition 
is an episode >5-6 minutes with a rate of >180 beats per minute (13, 85).
AHRE are common in pacemaker patients, 10-35% depending on the group 
studied (86, 87). In a meta-analysis AHRE strongly predicts clinical AF with 
an odds ratio of 5.7 and is associated with a 2.4-fold increase in stroke 
risk. The exact cut-off for AHREs differs between studies (87). Stroke risk 
scores, important in comparing the stroke risk in patients with AHRE to 
the stroke risk in clinically diagnosed AF, are not available for all stud-
ies. It is known that the stroke risk in patients with AHRE is lower than 
in patients with clinically diagnosed AF. AHRE can also be heart rhythms 
other than AF (87, 88). Stroke in patients with AHRE often appear without 
temporal relation to the high rate episodes (89-93), indicating that AHRE 
may be a risk marker rather than a direct cause for thromboembolism in 
these patients. However, AHRE lasting >24 hours display a strong associa-
tion with stroke (94). Interestingly, there is no correlation between AHRE 
and history of stroke, suggesting that AHRE might be caused by implan-
tation of pacemaker lead (86, 95). AHRE is common, however, not only in 
patients with pacemakers and defibrillators, but also in individuals with 
subcutaneous implantable devices, CHA2DS2-VASc score ≥2-3 and addi-
tional risk factors for AF (96, 97).
According to ESC guidelines, further ECG monitoring is regarded in patients 
with AHRE, to verify the AF diagnosis. OAC treatment is recommended 
only when the AF diagnosis can be verified by ECG (13). Large prospective 
randomised studies assessing the effect of OAC in patients with AHRE are 
under way (98, 99). 
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2 AIMS OF THE THESIS
2.1 Overall aim
The hypothesis was that extended screening and follow-up in elderly patients 
with a high risk of stroke (CHA2DS2-VASc-score ≥ 2) and short episodes of 
atrial-fibrillation (AF)-like activity (micro-AF) detects a significant propor-
tion of silent and previously undiagnosed AF compared to patients without 
micro-AF. The following intermediate aims were set up:
2.2 Specific aims of the thesis
• To study the prevalence of micro-AF in an elderly population
• To postulate the time span from micro-AF to clinically manifest AF 
• To assess if number and duration of micro-AF episodes predict 
development of AF
• To compare AF detection between continuous and intermittent 
ECG recording
• To compare participants’ willingness to use continuous and inter-
mittent ECG
• To study the prognosis, including mortality, stroke and develop-
ment of AF in patients with micro-AF, other supraventricular 




3 MATERIALS AND METHODS 
3.1 Study population
The participants in study I and IV derived from STROKESTOP I, a popu-
lation-based cohort study, to which all 75- and 76-year olds living in the 
Stockholm County or Halland region were randomised 1:1 to be included 
in the AF screening programme. Inclusion was ongoing from 2012 to 
2014. All participants in the screening group without previously known AF 
(n=6955) were asked to perform 30 seconds ECG recordings twice daily for 
two weeks using an intermittent device from Zenicor. Upon inclusion the 
participants were asked to fill out questionnaires with regards to medical 
history and to self-assess their weight and height (only Stockholm arm). 
They also had their pulse controlled and blood pressure measured (9). 
The participants in study II and III were recruited from the STROKESTOP 
II study population. STROKESTOP II was also a mass-screening study 
for AF in 75- and 76-year olds. All residents in Stockholm County were 
randomised 1:1 to participate in the screening procedure or to serve as a 
control group. Participants were included from 2016 to 2018. Only indi-
viduals in the screening group without known AF and with N-terminal pro 
b-type natriuretic peptides (NT-proBNP) levels ≥125 ng/L (n=3766) partici-
pated in the two-week, extended AF screening using intermittent ECG four 
times daily (100). The study protocol of STROKESTOP II is similar to the 
earlier protocol of STROKESTOP I in most aspects. The main differences 
were that participants were instructed to make more frequent intermittent 
recordings and the group performing extended screening using intermit-
tent ECG during STROKESTOP II was smaller as NT-proBNP was used to 
identify high-risk individuals to reduce the screening burden. 
3.2 Screening methods
Two different ECG devices were used for AF screening in the studies 
included in this thesis; hand-held intermittent ECG using a Zenicor II 
device (Zenicor Medical Systems, Stockholm, Sweden, see figure 6) and 
continuous event-recording using an R-test 4 evolution device (Novacor, 
Rueil Malmasion, France, see figure 7). Both of these one-lead devices are 
already used in clinical practice and have been previously evaluated with 
regards to AF detection. 
The intermittent ECG has a 92% sensitivity and a 96% specificity for AF 
detection compared to 12-lead ECG (57). Every registration has a duration 
of 30 seconds, and placing thumbs at two electrodes performs the record-
ing. The data is transmitted to the software immediately. The device has 
a button for marking if symptomatic arrhythmia occurs.  
18
Figure 6. Handheld intermittent ECG device - Image courtesy of Zenicor 
The algorithm of the continuous event-recorder has a 92% sensitivity 
and a 87% specificity for AF detection compared to continuous ECG (59). 
It has a monitoring capacity of 32 days and can store up to 60 minutes 
ECG. The device can be set to store a certain number of episodes of each 
arrhythmia of interest. It can also be activated manually if symptomatic 
arrhythmia occurs. 
Figure 7. Continuous event-recorder - Image courtesy of Novacor
The participants in all our studies were asked to fill out a form to report 
if and when they had symptoms during screening. 
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3.3 Diagnostic criteria for micro-AF and AF
Micro-AF was defined in study I as abrupt onset episodes of ≥4 consecutive 
supraventricular beats with irregular rate-to-rate intervals and absence 
of regular p-waves, lasting for <30 seconds. As an effort to make micro-
AF easier to identify in clinical practise, we decided to change the criteria 
before inclusion started in the later studies. In studies II and IV, micro-AF 
was defined as abrupt onset episodes of tachycardia (>100 beats/minute) 
with ≥5 consecutive supraventricular beats, irregular rate-to-rate intervals, 
absence of regular p-waves and lasting for <30 seconds (see figure 8). AF 
was defined according to ESC guidelines as an irregular heart rhythm with 
absence of p-waves, lasting for at least 30 seconds (13). 
Figure 8 – Example of a micro-AF episode.
3.4 Study I
Towards the end of inclusion in STROKESTOP I the investigators noticed 
that some participants had shorter runs of AF-like activity and began to 
mark them for follow-up. After 2.3 years participants with micro-AF still 
free from AF along with a control group matched for CHA2DS2-VASc score 
and inclusion date were invited to participate in this prospective cohort 
study. Participation rate was 64% (n=47/74) in the micro-AF group, and 
the control group included an equal number of participants (see figure 9). 
The participants were once again asked to fill out a questionnaire regarding 
their medical history and had their pulse and blood pressure measured. 
The participants did repeat AF screening, performing intermittent ECG for 
30 seconds, twice daily along with continuous event-recording in parallel 
for two weeks. Participants who had significant arrhythmia detected were 
offered cardiologist follow-up. 
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Figure 9. Participation and screening procedure in study I. Reprinted courtesy 
of The American Journal of Cardiology: 2018;122(7) Elsevier Inc.©
3.5 Study II
Study II was also a prospective cohort study. During STROKESTOP II an 
algorithm was used to detect ECGs with arrhythmia (101). Specially trained 
nurses manually annotated all suspected micro-AF episodes. The investiga-
tors verified each micro-AF episode. Individuals with micro-AF were asked 
to participate in extended AF screening using continuous event-recording 
for two weeks. An unmatched control group in STROKESTOP II did con-
tinuous event-recording in parallel with intermittent ECG. Individuals 
in the control group with micro-AF seen during intermittent ECG were 
transferred to the micro-AF group, resulting in a micro-AF group with 
200 participants and a control group with 250 participants (see figure 10). 
Figure 10. Participation and screening procedure in study II. Reprinted courtesy 
of BMC Cardiovascular disorders: 2020;10;20(1):167 The authors ©
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3.6 Study III
Study III was a prospective method comparison study. It included the 
participants who did recordings using two screening methods in parallel 
during STROKESTOP II, most of whom were also included in the control 
group in study II. During their two weeks ECG registration, they were also 
asked to fill out a questionnaire with regards to comparing compliance 
and ease of use of the two devices. The following questions were included:
1) Was the device  
difficult to use? 
2) Which problems 
did you have with 
the device?
3) Were you able 
to finish the 
recording?
4) If not, what was 
the problem leading 
to discontinuation? 
5) Did the recording 
affect your daily life? 
6) Did the recording 
have effect on your 
experienced health?
Question 1 was answered on a graded ordinal scale from 1-5. Question 2 
and 4 were answered in free text. Questions 3, 5 and 6 were answered as 
yes/no. The answers to questions 2 and 4 were analysed together, as the 
questions were found to be asking for the same information. The answers 
to question 3 were found to be abundant as we had direct access to actual 
registration times for each individual and could therefore compare those.
3.7 Study IV
In this retrospective cohort study, all ECGs belonging to AF-free individu-
als in STROKESTOP I were re-evaluated using an automated algorithm to 
detect all cases of micro-AF. The algorithm also identified SVTs without AF 
characteristics, episodes of SVEBs in bigeminy/trigeminy and individu-
als with frequent isolated SVEBs (top tenth percentile). The arrhythmias 
detected by the algorithm were manually examined to confirm the findings. 
Participants were divided into arrhythmia group by the most pathological 
arrhythmia identified (see figure 11). All participants were followed for at 
least three years in patient registers from the National Board of Health and 
Welfare and in the Cause of Death Register. The primary endpoint was AF 
and secondary endpoints were stroke and death. Comorbidity data was 
also collected from registers. 
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For all continuous variables included in the studies of this thesis, histo-
grams for assessment of normal distribution were visually interpreted and 
Shapiro-Wilks test was performed. Non-normally distributed continuous 
variables are reported as median (IQR) and analysed using Mann-Whitney 
U- test. Normally distributed variables were reported as mean ±(SD) and 
analysed using: Paired Sample t-test in study I, Independent Samples t-test 
in study II, Paired Sample t-test in study III and Independent Sample t-test 
in study IV. Ordinal variables were reported as median (IQR) and analysed 
using Mann-Whitney U- test. For dichotomous variables presented as pro-
portions, Chi-square and Fisher’s exact test was used. Comparisons of the 
screening methods were performed using McNemar’s test.
No power calculations were performed for the studies included in this 
thesis; study I was a pilot-study, study II included all participants with 
micro-AF in the cross-sectional STROKESTOP II, study III was an explora-
tive study and study IV included all participants from the cross-sectional 
STROKESTOP I study.
For all statistical analyses, the significance threshold for the p-value was 
set to <0.05. The analyses in study I-III were performed using IBM SPSS 
statistics, version 24 software (IBM SPSS Statistics, IBM Corp, Somers, 
NY). For analysis in study IV Stata versions 14 and 16 (Stata Corp., College 
Station, TX, USA) was also used.
4.2 Study I
The micro-AF group had matched controls and the groups were compared 
pairwise. For uni-and multivariable analyses, logistic regression analysis 
was used. All variables that were significant during univariate analysis 
were included in multivariable analysis. 
4.3 Study II
Micro-AF participants were compared to an un-matched control group 
as independent samples. Logistic regression was used for multivariable 
analyses. Most significant variables from univariate analysis were included. 
The number of SVEBs per 30-second intermittent ECG, however, was not 
included in the multivariable analysis due to interaction with presence of 
micro-AF. Time between use of the two different ECG methods was also 
excluded from the multivariable analysis as it correlated to participation in 
the micro-AF group and implied a risk for reversed causation. In addition, 
potential confounders as identified by the HATCH-score  (hypertension, 
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stroke/TIA and heart failure) – which is one risk score to predict AF – 
were included in the multivariable model. A stratified analysis was used 
to compare micro-AF as a predictor for AF in men and women separately. 
4.4 Study III
This is a method-comparison study, the participants were their own con-
trols. No multivariable analysis was performed. 
4.5 Study IV
The different arrhythmia groups were unmatched and compared as inde-
pendent samples. The CHA2DS2-VASc score parameters were considered 
potential confounders and were adjusted for during Cox regression analy-
sis, except from thromboembolism due to risk of co-variation with AF. 




All research projects included in this thesis, except study IV, depend on 
participation of patients and healthy controls. All studies comply with the 
Declaration of Helsinki, the protocols are approved by the regional ethics 
committee and all participants gave their informed consent. Still, to screen 
for a disease in individuals free from symptoms can be controversial when 
the treatment offered entails risks. In this case untreated AF was believed 
to impose greater risk than the treatment itself.  
Some individuals suffered from discomforting itching and eczema from 
the continuous event-recorder patches. In addition to physical discom-
fort, participation could also cause anxiety, a psychological discomfort. 
Participants with micro-AF were told about the irregularity in heart rhythm 
and received information about the increased risk of AF. Individuals with 
no AF found during repeat screening may have continued to worry about 
developing AF or may have regarded themselves as free from AF even 
though the screening result could be falsely negative and the disease may 
be of progressive nature.
The potential benefits of participation for the individual participants and 
the society were considered to be large, as strokes produce high patient 
suffering and high costs. The potential risks and suffering connected to 
participation were small. 
The privacy violation is considered exiguous as sensitive personal data 
was collected first after informed consent was given. All personal data was 
stored in a safe database provided by Zenicor. Participants were also fol-
lowed in patient registers from the National Board of Health and Welfare 
as well as in the Cause of Death Registry.
The person who invited a potential participant was not the treating physi-
cian, and the potential participant did not depend on him/her in any medi-
cal or health care sense. This lowered the risk of patients experiencing the 
feeling of being forced to participate. Early dropouts from a study also did 
not affect the follow-up; all participants in whom significant arrhythmia 
was found were offered a cardiologist follow-up. Individuals that could 
potentially have suffered from the inconvenience of participating in the 
study were the same as the group of the Swedish population that could 
most likely benefit from the impact of a positive result.
All participants diagnosed with AF in the studies were after individual risk 
examination initiated on OAC treatment in accordance with ESC guidelines 
(13). The treatment itself is known to increase the risk of bleeding, but 
in the majority of patients with AF, the risk of ischemic stroke outweighs 
the bleeding risk. 
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6 RESULTS PER STUDY
6.1 Study I
Participation in the micro-AF group – including individuals clinically diag-
nosed with AF during follow-up, was 73% (n=54/74) and 74% (n=48/65) 
in the control group. Median time to follow-up was 2.3 years. The time to 
follow-up was longer in the control group (p<0.001), where participants 
hence got older (p<0.001). Control group participants also had higher sys-
tolic blood pressure (p=0.03). The micro-AF group had more SVEBs than 
the control group (p<0.001). Apart from this, the groups were similar in 
baseline characteristics. 
In the micro-AF group, 45% (21/47) were diagnosed with AF during repeat 
screening. Including individuals clinically diagnosed with AF during the 
two-year follow-up period, 50% (27/54) received an AF diagnosis. One indi-
vidual in the control group had been diagnosed with AF during follow-up. 
Including this individual and after repeat screening, 10% (5/48) of partici-
pants in the control group had received an AF diagnosis. The difference is 
significant, p<0.001. All participants with AF diagnosed before and during 
screening were initiated on OAC treatment. For patients in the micro-AF 
group more SVEBs, more frequent episodes of micro-AF and longer episodes 
were associated with the development of AF. In multivariable analysis only 
increased amount of SVEBs remained significant (see table 2). 
Table 2. Multivariable analysis for the development of AF. Reprinted courtesy of 
The American Journal of Cardiology: 2018;122(7) Elsevier Inc.©
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More cases of AF were detected using continuous event-recording (n=25) 
than intermittent ECG (n=10), p<0.001. No AF cases were detected only 
by intermittent ECG. 
6.2 Study II
Of participants in STROKESTOP II, 6% had micro-AF. Of that micro-AF 
cohort, 89% (n=196/221) participated in the micro-AF follow-up study. 
Participants in the control group were older (p<0.001), more frequently 
had diabetes mellitus (p<0.001), were shorter (p=0.035), had less SVEBs 
(p<0.001) and had higher CHA2DS2-VASc scores (p=0.01). The CHA2DS2-
VASc scores were similar to study I. As per study design participants in 
the micro-AF group had longer follow-up time to extended screening (3.3 
months) compared to the control group who were screened using both 
ECG modalities in parallel, p<0.01. In both study I and II, participants 
with micro-AF had significantly longer analysable signalling time for the 
continuous event-recorder. Most participants in study I and II had only one 
episode of micro-AF, and the episodes were short (5-6 beats on average). 
As in study I total AF prevalence was four-five-times higher in the micro-
AF group compared to the control group. In the micro-AF group, AF was 
detected in 13% (n=26/196) of participants and in 3% (n=5/33) in the 
control group. All individuals with detected AF were also in this study 
initiated on OAC treatment.
Participants diagnosed with AF were taller, had longer analysable signal-
ling time for continuous event-recording, more frequent micro-AF episodes 
with longer duration and more SVEBs (p<0.001 for all comparisons). 
Presence of micro-AF remained a strong predictor for AF through the dif-
ferent multivariable models (see table 3), but micro-AF burden (duration 
and frequence of episodes) did not.  
Table 3. Multivariable analysis for the development of AF. Reprinted courtesy of 
BMC Cardiovascular disorders: 2020;10;20(1):167 The authors ©
Further multivariable analysis showed that micro-AF was a stronger pre-
dictor for AF in men than in women. 
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6.3 Study III
Seven percent (n=269) of the participants in STROKESTOP II were included 
in this sub-study from June 2017 to January 2018. AF was detected in 
6% (n=15) of those participants when using continuous event-recorder 
and in 2% (n=5) when using intermittent ECG. All cases of AF detected 
by intermittent ECG were also detected by continuous event-recording. 
Continuous event-recording had detected significantly more AF compared 
to intermittent ECGs already after three days of screening (see figure 12). 
Figure 12. Time until detection of first episode of AF using intermittent ECG recordings 
and continuous event-recording. Reprinted courtesy of Clinical Cardiology: https://
doi.org/10.1002/clc.23323 Clinical Cardiology published by Wiley Periodicals, Inc.©
In this study AF detection was three-times higher using continuous event-
recording compared to intermittent ECG, which is similar to 2.5-times in 
study I. With regards to detection of other significant arrhythmias, the 
detection rates were generally higher for continuous event-recording. In 
total, 35 participants were referred for further investigation due to arrhyth-
mia findings other than AF. 
The algorithm used for detection of AF on intermittent ECGs did not miss 
any suspected episodes of AF found by manual interpretation. For con-
tinuous event-recording, 27% of the episodes verified as AF after manual 
interpretation were categorized by the algorithm as other arrhythmias. This 
led to a need for interpretation of all episodes categorised as  arrhythmia 
by the continuous event-recorder, with an interpretation burden per 
participant of 55 (IQR 40-70) ECGs. For intermittent ECG, only episodes 
marked as suspicious AF by the algorithm needed manual interpretation. 
The interpretation burden for intermittent device was 3 (IQR 1-8) ECGs.
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Participants were instructed to make a minimum of 56 intermittent ECGs 
and did 55 (IQR 40-70), 98% of expected. They were instructed to wear the 
continuous event-recorder for 14 days and were monitored to have done 
so for 13.3 (IQR 11.8-13.9) days, 94% of the expected time. Presence of 
palpitation symptoms did not affect compliance, neither for intermittent 
ECG (p=0.559) nor for continuous event-recording (p=0.804).
Figure 13. Results from forms completed by the participants regarding use of the two 
different screening devices. Reprinted courtesy of Clinical Cardiology: https://doi.
org/10.1002/clc.23323 Clinical Cardiology published by Wiley Periodicals, Inc.©
The participants preferred the intermittent ECG screening method with 
regards to nearly all comparisons (see figure 13). 
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6.4 Study IV
Out of 6,289 participants free from AF in STROKESTOP I, 6,100 were 
included in this study. They had performed a median of 29 (CI 22.5-35.5) 
ECGs each.  Of those participants, 15% had supraventricular arrhythmias 




























5,206 709 48 39 1 97
Table 4. Number of participants with each type of supraventricular arrhythmia. 
SVEBs indicate supraventricular ectopic beats. SVT indicates supraventricular 
tachycardia. 
Median time to follow-up in registers was 4.2 (IQR 3.8-4.4) years. During 
follow-up 387 participants had received an AF diagnosis, 161 had suf-
fered from stroke and 354 had died. The group with highest cumulative 
incidence of AF was the micro-AF group, with an incidence of nearly 20%. 
Figure 14. Kaplan-Meier curves showing primary end-point event rate (atrial 
fibrillation) in participants with different arrhythmias.
After adjustments for potential confounders, frequent SVEBs (including iso-
lated, bigeminal or trigeminal) were associated with a hazard ratio of 2.1 (CI 
1.6-2.7) for AF, and presence of any SVT was associated with a hazard ratio 
of 3.1 (CI 2.1-4.6) for AF (see figure 14). Of SVTs with different characteristics, 
micro-AF was shown to be the strongest predictor for AF with a hazard ratio 
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of 4.3 (CI 2.7-6.8), even after multivariable adjustments. The study was not 
powered to evaluate the risk for stroke and there was no significant increase 
seen. However, the risk of death was increased for individuals with micro-
AF, hazard ratio 2.0 (1.1-3.8), after adjustments for potential confounders.
Most participants classified in the SVT-groups had SVTs with short 
 duration, 7 (IQR 6-12) beats, and most participants had only one SVT 
 episode, 1 (IQR 1-2). SVT burden did, however, did not remain a significant 
factor for development of AF in multivariable analysis. 
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7 GENERAL DISCUSSION 
7.1 Major findings
In the first pilot-study that evaluated micro-AF during intermittent ECGs 
as a predictor for future AF, we showed that individuals with micro-AF 
have a five-fold increased risk of AF after two years. Nearly 80% of indi-
viduals with micro-AF that were diagnosed with AF were not diagnosed 
before repeat screening. 
The second study was also an investigation of micro-AF seen during inter-
mittent ECGs in elderly individuals. By extended screening with a three-
month delay, AF was shown to be four-times more common in individuals 
with micro-AF in comparison to individuals without the finding.  
In the third study, an ambulatory elderly population was screened using 
intermittent ECG and continuous event-recording in parallel for two 
weeks. Intermittent ECG was considered user-friendlier than continuous 
event-recording, but compliance with both screening methods was good. 
Three-times more new cases of AF were detected using continuous event-
recording compared to intermittent ECG.
The fourth study was a comparison of prognosis in elderly individuals 
with different kinds of supraventricular activity seen during intermittent 
ECG. SVTs were shown to be a stronger predictor of future clinical AF than 
SVEBs. Of the SVTs, micro-AF stood out as the strongest predictor for a 
future clinical AF diagnosis and was also associated with an increased 
risk of death. After four years of follow-up, clinically diagnosed AF was 
four-times more common in the micro-AF group compared to the non-
arrhythmia group. 
With extended screening after three months in study II, 13% of partici-
pants with micro-AF were diagnosed with AF, compared to 50% after two 
years in study I. Only 5% had clinically detected AF before repeat screen-
ing, after two years in study II. After four years 20% of participants with 
micro-AF were clinically diagnosed with AF in study IV. This indicate that 
micro-AF can probably be both interpreted as a signal for unknown AF and 
a preliminary stage to AF, as the prevalence seems to increase over time. 
The detection of AF in elderly individuals with micro-AF can be delayed 
and the diagnosis may even be undiscovered if screening is not practiced. 
Extended and repeat screening for AF could be recommended elderly 
individuals with micro-AF as a finding of AF in most cases would lead to 
initiation of OAC. A long-time continuous screening method is preferable 
in such a high-risk population.
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7.2 Different types of supraventricular activity 
In study IV, SVTs were shown to be associated with a three-times increase 
in risk of AF and in participants with frequent SVEBs, the risk was dou-
bled compared to in the non-arrhythmia group. There were no significant 
differences with regards to stroke or all-cause mortality comparing these 
groups. In a study by Johnson et al., no difference in prognostic signifi-
cance was found between frequent SVEBs and SVTs (74). Other studies 
have focused mainly on analysing excessive supraventricular activity as 
a combined variable independent of classification (79).
In study IV micro-AF was shown to be associated with a four-fold increase 
in risk of clinically detected AF while irregular SVTs with p-waves were 
associated with a three-fold increased risk. The risk increase was not sig-
nificant in individuals with regular SVTs with p-waves. Our study was not 
powered to compare differences in stroke risk and all-cause mortality, but 
individuals with micro-AF had a doubled risk of death. Similar results were 
found in a study by Johnson et al.; micro-AF was shown to be associated 
with a five-fold increase in risk of clinically detected AF while irregular SVTs 
with p-waves were associated with a three-fold increase. They identified 
more episodes of regular SVTs without p-waves than we did. Interestingly, 
these episodes were associated with a three-fold increase in risk of AF and 
were the only supraventricular arrhythmia associated with stroke, with a 
14-fold increased risk (84).
In study II, using extended screening, individuals with micro-AF were 
shown to have an absolute risk of earlier undetected AF of 13%. The risk 
of screening detected AF within three months in individuals with micro-
AF is 65% of having it clinically detected after four years (13% divided by 
20%). If this known relationship is extracted to other arrhythmias in study 
IV, 7% of individuals with frequent supraventricular ectopic beats would 
have had AF detected by repeat screening within three months, and 10% 
of participants with SVTs independent of characteristics would have had 
AF detected. One can hypothesise that these groups may also benefit from 
extended AF screening. We do not know, however, if the development of 
AF in these individuals with other arrhythmias follows the curve of micro-
AF patients.  
An association with general prothrombotic atrial myopathy may explain the 
increased risk of AF and stroke seen in individuals with short SVTs with 
AF characteristics in comparison to patients with other atrial tachycardias. 
The increased risk of stroke in patients diagnosed with AF is thought to be 
explained, at least partly, by atrial myopathy (32). Regular SVTs like ectopic 
atrial tachycardia, atrial flutter and atrioventricular nodal re-entry tachy-
cardias are caused by smaller focal atrial defects (102) and are not neces-
sarily associated with general atrial myopathy. Although, non-classified 
SVTs are to some extent associated with an elevated risk of stroke (103). 
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7.3 Stroke risk in atrial fibrillation with varying 
duration and symptoms 
It has frequently been discussed whether or not screening detected AF is 
associated with the same stroke risk as clinically diagnosed AF, as partici-
pants with screening detected AF are thought to have less symptoms and 
a lower AF burden (104). In study II, 15% reported typical AF symptoms 
during their participation in the study, but no-one reported AF symptoms 
at the exact time when AF was seen during the recording. As the study 
populations were the same, neither did participants diagnosed with AF in 
study III report symptoms at the time of the event. The total AF burden in 
participants diagnosed with AF in study II and III was 1-2% during two-
weeks continuous event-recording (105). 
Asymptomatic AF is associated with an increase in stroke risk and all-
cause mortality compared to no AF (63, 86). A meta-analysis including six 
different studies of individuals with symptomatic and asymptomatic AF 
found no difference in stroke rate or all-cause mortality. It concluded that 
presence of symptoms should not determine the treatment approach (62). 
The CHA2DS2VASc score system has not been validated for use in deter-
mination of OAC treatment in patients diagnosed with AF during long-
term ECG recording (106). According to a meta-analysis that includes 12 
studies (107), long-standing AF is associated with a higher risk of stroke 
when compared to paroxysmal AF. However, it is unknown if the increase 
in stroke risk may be related to increased prevalence of co-morbidities. 
Paroxysmal AF is still associated with an increased risk of stroke and 
often progresses to non-paroxysmal forms (108). Also, OAC treatment in 
individuals with high CHA2DS2VASc scores has been shown, independent 
of AF diagnosis, to be beneficial (31). AF burden may therefore only be of 
importance for individuals with a low underlying risk of stroke, men with 
CHA2DS2VASc score 1 and women with CHA2DS2VASc score 2 (13). In our 
studies all participants diagnosed with AF had indication for OAC treat-
ment as their median score was 3 (3-4). 
It remains to be investigated if individuals with screening-detected AF have 
the same risk of stroke as asymptomatic patients with low AF burden. 
According to ESC guidelines, ECG-verified screening-detected AF is treated 
in the same way as clinically diagnosed AF. It is not recommended to take 
AF burden and symptoms into account (13). All participants included in 
our studies with AF lasting for at least 30 seconds were initiated on OAC 
treatment. 
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7.4 Screening in specific risk groups 
AF is a common disease, affecting at least 3% of the adult population in 
Sweden (2). The prevalence is expected to double within 50 years from now 
(5, 6). AF is associated with a five-fold increase in stroke risk and a doubled 
risk of death (13, 15). The risk of stroke in AF patients decreases at least 
64% using OAC compared to placebo (39). Among patients with AF, about 
one third are thought to be asymptomatic and 25% have paroxysmal AF 
(109, 110). AF is therefore difficult to diagnose and an under-diagnosed 
condition (9). Stroke can be the first manifestation of AF; in 10% of people 
diagnosed with stroke AF is detected first at the time of the event (111). 
These factors together have made screening for AF a subject of interest in 
an effort to increase AF detection and offer early OAC treatment. 
Several strategies have been tested to try to reduce the numbers needed 
to screen and still detect AF in those with high risk of stroke. For patients 
with confirmed stroke or TIA, ESC guidelines already recommend screen-
ing for AF (13).
The prevalence of AF increases steeply with age (3). AF detection is very 
low in individuals aged <65 years (47). Age is also one of the strongest 
predictors for stroke in AF patients (112). According to ESC guidelines 
systematic screening for AF may be considered in individuals >75 years 
of age or those at high risk of stroke (13). 
CHA2DS2-VASc score is commonly used to predict stroke risk in AF patients 
but can also be used to identify individuals with an increased risk of hav-
ing AF (113). 
NT-proBNP is one of the strongest predictors for AF (114) and is also 
associated with an increased risk of stroke in AF patients (115). In the 
population-based screening study for AF, STROKESTOP I, all participants 
randomised to screening did intermittent ECG recordings for two weeks. 
In STROKESTOP II all participants randomised to screening did an index 
ECG, but only participants with elevated levels of NT-proBNP did inter-
mittent recordings for two weeks. On index ECG a markedly higher pro-
portion of participants with elevated NT-proBNP were diagnosed with AF 
compared to the low-risk group, indicating that NT-proBNP is usable as 
a discriminative biomarker. Also, a similar proportion of newly detected 
AF was found in the two screening studies, despite that the number of 
participants performing two-weeks intermittent ECG was reduced by 41% 
in STROKESTOP II (9, 116). 
In our studies micro-AF seems to be a remarkably strong predictor for AF 
and also a predictor for death. An earlier study has shown that the stroke 
risk in individuals with excessive supraventricular activity and CHA2DS2-
VASc -score ≥ 2 is comparable to the stroke risk in AF patients, 2.4 % 
per year (82). Selection of screening populations based on variables both 
associated with an increased risk of AF and stroke is optimal. The difficulty 
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with use of micro-AF for guidance of whom to screen is that a first screen-
ing step is needed to detect micro-AF. Despite this difficulty it is a valu-
able source of guidance of who to screen repeatedly and more extensively. 
7.5 Population-based screening
Opportunistic screening for AF by pulse palpation or single ECG strip is 
recommended in individuals >65 years (13). There are several ongoing 
large-scale screening studies from which long-term data with regards to 
hard endpoints will be available. The results of these studies may help to 
determine if the stroke risk in screening detected AF is similar to the risk 
in clinically diagnosed AF and if a systematic nation-wide screening pro-
gram for AF could be cost-effective and life-saving (104). One suggested 
age for population screening is 75 years, as current ESC guidelines rec-
ommend OAC treatment in individuals ≥75 years old with AF regardless 
of co-morbidities (13). In addition, a simulation study has concluded that 
screening at the age of 75 may result in the lowest cost per quality-ad-
justed life-year gained (117).
Non-participants in AF screening studies have been shown to have more 
co-morbidities and higher incidence of stroke than participants (118). 
The non-participants are probably also more likely to have AF. Rates of 
attendance to screening programs are also affected by socio-economic sta-
tus (119, 120). In STROKESTOP I non-participants had lower education, 
lower income levels and were more commonly immigrants (121). Travel 
distance to screening centres also affected participation and is probably 
more likely to affect participation in high-risk individuals. Not reaching 
out to the most vulnerable groups can potentially lead to under-diagnosis 
and under-estimation AF prevalence. Easy access to screening centres 
and information available in different languages might be important in 
study design. 
The optimal choice of screening method may depend on the population 
screened, their risk of AF and stroke. In study III we saw that intermittent 
ECG detected a significant number of new AF cases in an elderly popula-
tion (2%), but detection using continuous event-recording for the same 
period of time was three-times higher (6%). Both screening devices were 
well-tolerated in an elderly population, but participants liked the inter-
mittent ECG better.  
The yield of AF, of course, depends a lot on the underlying prevalence in 
the population screened and the screening method. In the REHEARSE-AF 
study the prevalence of screening detected AF was found to be 3% as in 
STROKESTOP I and II. The participants had a mean age of 72.6 years and 
CHA2DS2VASc score of 3. They did intermittent ECGs using the AliveCor 
Kardia system twice per week for a year (122). A considerably higher preva-
lence of new AF was detected in the ASSERT-II study  including participants 
with a mean age of 74 years and CHA2DS2VASc score of 4.1. Implantable 
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subcutaneous ECG monitoring was used for screening. After 1.3 years 34% 
of participants were diagnosed with AF (86). In the REHEARSE-AF study, 
an episode of AF-activity had to last at least 30 seconds for diagnosis. In the 
ASSERT-II study, an episode had to last for at least five minutes to be included.
A multi-step approach to screening may be optimal for high yield of AF detec-
tion, but still to a lower cost and need of less resources. In STROKESTOP 
II all participants did an index ECG, only participants with NT-proBNP 
≥125 ng/L were screened with intermittent ECG for two weeks (116). Still, 
the total prevalence of newly detected AF in participants randomised to 
screening in STROKESTOP II was similar to that found in STROKESTOP I. 
After extended screening in participants with micro-AF in STROKESTOP II 
the AF prevalence was increased by 22%, with only 200 participants more 
extensively investigated. Intermittent ECG could possibly also be replaced 
by more extensive screening using a continuous device in known high-risk 
participants at inclusion, for example with CHA2DS2-VASc score >3 in men 
and >4 in women or NT-proBNP above a certain level. 
In STROKESTOP II individuals with NT-proBNP ≥900 ng/L were considered to 
have high risk of having heart failure and were referred to echocardiography 
(123). This cut-off level could possibly also be used to identify individuals 
with an increased risk of AF where prolonged screening might be of value as 
the diseases are often seen together. Individuals with NT-proBNP ≥ 290ng/L 
have compared to ≤ 51ng/L, been shown to have a four-fold increase in risk 
of clinically detected AF after adjustments for potential confounders (114). 
7.6 Primary prevention for atrial fibrillation  
For individuals with micro-AF and for whom OAC is not yet known to be 
effective, primary and secondary prevention of AF can be of interest (14). 
The same actions may also decrease the supraventricular burden and 
atrial myopathy. Management of adjustable risk factors such as hyperten-
sion, diabetes mellitus, sleep apnoea, physical inactivity and obesity may 
prevent progression from micro-AF to AF.
An elevated risk for AF has been seen in individuals with poorly controlled 
blood pressure (124). Some of the hypertension treatments have been 
shown to reduce AF recurrence and burden (14). In our study participants 
seemed to have well-regulated blood pressure, and hypertension was not 
found to be more common in participants with micro-AF and AF. 
Individuals diagnosed with diabetes mellitus seem to have a 40% higher risk 
of AF, and that risk is associated with poor glycaemic control. Participants 
with micro-AF did not have a higher prevalence of diabetes mellitus in our 
studies, but we do not have access to information regarding blood sugar 
regulation. AF was also not more commonly diagnosed in our study par-
ticipants with diabetes mellitus.
39
Observational studies have shown an association between sleep apnoea 
severity and incidence as well as burden of AF (14). Individuals with AF 
and sleep apnoea using CPAP seem less likely to develop more permanent 
forms of AF (125).
Physical inactivity seems to independently affect the AF burden, not only 
depending on comorbidities. Physical activity may reduce the risk of new 
onset AF (14). Extreme physical activity, however, like marathon running, 
is associated with a nearly nine-fold increase in risk of AF (126).
Obesity is a strong risk factor for AF and seems to affect both develop-
ment of disease and AF burden (14). It is known that weight loss ≥10% in 
obese individuals diagnosed with AF is associated with a six-times longer 
arrhythmia-free survival rate (127). Most participants in our studies both 
with micro-AF and AF had a BMI of around 25.
To reduce the risk for AF and reduce the AF burden it is recommendable to 
strive for BMI ≤25 kilograms/meter² and to incrementally increase physical 
exercise up to the moderate-intense level with a duration of 200 minutes 
per week. Smartphones and dietary apps that can provide feedback to users 
are suggested to facilitate these goals. Another alternative is weight loss 
programs. Blood sugar control in diabetes patients as well as well-treated 
hypertension may also be beneficial. Screening for sleep apnoea and CPAP 
treatment when indicated is also recommended (14). These recommenda-
tions may be beneficial, even for individuals with micro-AF.  
7.7 Limitations 
The knowledge about micro-AF from the studies included in this thesis is 
limited to an elderly population and most participants were Caucasian. 
This may affect the external validity. Another study, however, of younger 
participants (mean age of 64.5 years) with irregular SVTs showed similar 
results (84). All study participants were recruited from STROKESTOP I and 
II. It is possible that individuals participating in these screening studies 
were healthier than the general population (128). Participants in screen-
ing might also be more highly motivated than the general population. In 
study III, compliance to both screening devices was high, particularly to 
continuous event-recording that was considered less user-friendly, com-
pliance could be assumed to be lower in a real-world setting.
AF is more common in individuals with increased levels of NT-proBNP 
(114). The participants in study II and III all had elevated NT-proBNP lev-
els. The AF prevalence found in these studies may not be representative 
of the general population. Subsequently, micro-AF prevalence in study II 
may also have been overestimated. It is possible that micro-AF is a stronger 
predictor for AF in individuals with elevated NT-proBNP. As participants 
in study III were their own controls, this did not affect the comparison. 
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Our studies have covered extensive but still limited screening for AF at 
two specific time-points – after three months and two years. AF cases may 
thus have remained undetected. To really know the progression rate from 
micro-AF to AF, years of internal loop-recording may be needed. By use 
of registry diagnosis in study IV, subclinical cases of AF and stroke can-
not be accounted for leading to weakening of the statistical associations. 
Participants in STROKESTOP I were screened using intermittent ECG, it 
is unknown how much AF would have been detected if continuous event-
recording would have been used instead. This makes it difficult to conclude 
from study I if micro-AF should be considered a sign of undetected AF or a 
preliminary stage to AF. The AF prevalence found in individuals with micro-
AF, however, was significantly higher in study I after two years compared to 
in study II, after three months. In study II the micro-AF group underwent 
extended AF screening three months later than the control group. More 
cases of AF may have been found in the control group using the same time 
to follow-up. This may have caused an overestimation of our findings. 
From our studies we cannot draw any conclusions regarding importance of 
micro-AF burden. Although there were significant differences in duration 
and number of micro-AF episodes between individuals diagnosed with AF 
and those who were not, the differences did not remain significant in mul-
tivariable comparisons. Neither were our studies powered to evaluate the 
stroke risk in individuals with supraventricular arrhythmia. The results 
may have been different with a prolonged time to follow-up. 
Both the intermittent ECG and the continuous event-recorder are one-lead 
devices. P-wave analyses were sometimes difficult; especially atrial flutter 
may have been missed. This introduces a risk of misclassification bias. 
From R-Test 4 full disclosure ECGs were not available for all suspicious 
AF episodes. Due to memory and storage limitations, not all episodes of 
suspected arrhythmia were stored. This made it difficult to determine the 
AF burden. As the device has a propensity to over-diagnose AF, manual 
inspection of the stored episodes was needed to diagnose AF. Some cases 
may have been missed due to limited storing capacity of the device. 
With the diagnostic criteria used for micro-AF within study I, an episode 
was difficult to identify, as it was short and not necessarily tachycardia. 
There is a risk that different types of supraventricular activity were clas-
sified the same. Therefore, to make the finding easier to identify in clini-
cal practice, we decided to prolong the needed duration and added the 
tachycardia criteria to micro-AF diagnostics. 
The researchers were not blinded in study I and II. During ECG interpreta-
tion it was known to which group the participants belonged, which could 
have caused bias. 
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8 CONCLUSIONS
Micro-AF is found in 2% of an unselected 75-76 year old population and 
in 6% of individuals with the same age and increased levels of NT-proBNP, 
using intermittent ECG. Elderly individuals with micro-AF seen during 
intermittent ECG have a four-five-fold increase in risk of both undetected 
and future AF compared to a control group. With a four-fold increase in AF 
prevalence after two years compared to after three months, the prevalence 
of AF seems to steeply increase over time in this group. Relation between 
micro-AF burden and AF development did not remain significant after 
multivariable adjustments. 
Extended and repeat screening for AF could be recommended given that a 
finding of AF in most cases would lead to initiation of OAC. In an ambulatory 
elderly population, intermittent ECG is more acceptable than continuous 
event-recording. Continuous event-recording, however, detects three-times 
as many new cases of AF compared to intermittent ECG when they are 
applied in parallel for two weeks. Accordingly, in a high-risk population, 
continuous event-recording albeit more time-consuming is the preferable 
choice of screening method due to higher AF detection rates than inter-
mittent ECG. 
All kinds of extensive supraventricular activity seem to be associated with 
an increased risk of AF, although more organized atrial arrhythmic epi-
sodes are increasingly associated with AF development. Individuals having 
SVTs with AF characteristics – micro-AF – have a higher risk of a future 
clinical AF diagnosis than patients with other supraventricular activity. 
Micro-AF is also associated with an increased risk of death, but no sig-




According to the present guidelines for AF, the definition of AF is an 
irregular heart rhythm without p-waves lasting a minimum of 30 seconds, 
a duration based on expert consensus rather than scientific data. Some 
earlier studies have already displayed a linkage between short episodes 
of AF-like activity and development of AF and stroke. An early diagnosis 
of AF and initiation of treatment with oral anticoagulants might lead to a 
significant reduction of the risk of a stroke in high-risk individuals. AF is 
often paroxysmal and asymptomatic which leads to diagnostic difficulties. 
Considering this, identification of risk factors for having or developing AF 
is important. It has been shown that micro-AF can be both a sign of an 
already existing AF and have a rapid progression rate to AF. A standard-
ised follow-up could therefore be recommended. This follow-up may lead to 
earlier AF diagnosis, risk-factor modification and might potentially reduce 




Primary preventive systematic screening for AF has not yet been shown 
to have an impact on the societal stroke burden or to be cost-effective. It 
is not known if AF cases detected by screening have the same beneficial 
effect of OAC as symptomatic cases. Although, it is known that they have 
an increased risk of stroke compared to the general population. Individuals 
with screening detected AF may also have less AF burden than individuals 
with clinically diagnosed AF. Whether or not the burden affects the stroke 
risk is still not fully known. Ongoing studies are evaluating the potential 
benefits of OAC in individuals with AHRE seen during long-term record-
ing and may answer this question. Five-year follow-up data from the AF 
screening study STROKESTOP I and long-term data from several other 
large randomised controlled screening studies will soon be available and 
may affect the recommendations regarding screening for AF. 
Different strategies for targeting only high-risk individuals with screening 
to reduce costs are discussed. As an effort to reduce the screening burden 
in the STROKESTOP II screening study, only individuals with increased 
levels of NT-proBNP, who were believed to have the highest risk of AF and 
stroke, were screened extensively. The studies included in this thesis indi-
cate that micro-AF could also be used for guidance with regards to which 
individuals with increased levels of NT-proBNP would benefit from even 
more extensive screening. 
It is still difficult to choose one optimal screening method for AF in high-
risk populations. We know that continuous methods used during long time 
periods detect more AF than intermittent ECG. The problems with skin 
irritation caused by the sticky patches used to apply continuous ECG must 
be solved. A continuous screening method that has good signal quality 
without using patches may eventually develop. That kind of a device would 
probably be optimal for use in high-risk individuals. Different wearable 
devices are now available also for use as self-screening. However, these 
devices, similar to most screening programs, tend to attract young and 
healthy individuals with low risk of both AF and stroke. We need strate-
gies to direct screening towards the groups that will benefit most from 
participation in it. 
The mechanism that leads to increased stroke risk in AF patients is still 
unknown. The risk increase has been explained for a long time to be due 
to changes in movement patterns of the atrium during AF. On the other 
hand, there are results that indicate that individuals diagnosed with AF are 
at increased risk of stroke even during long periods of sinus rhythm. One 
possible explanation for this phenomenon could be that AF may actually 
be a sign of prothrombotic atrial myopathy that leads to electrical distur-
bances. If that is true, short episodes of AF-like activity could potentially 
be seen as signs of atrial myopathy. This may explain the results of register 
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studies in which individuals with really short episodes of AF-like activity 
have been shown to have an increased risk of stroke. Further research is 
needed to clarify if episodes of AF-like activity shorter than 30 seconds 
may merit OAC treatment. 
The association between AF and dementia seen in register studies has 
been discussed a lot lately. The relationship may be explained by silent 
infarcts and vascular lesions caused by micro-embolism. There are no 
results available with regards to risk of dementia in patients with exces-
sive supraventricular activity. An increased risk of dementia in individu-
als with micro-AF would potentially motivate initiation of OAC treatment 
as well. As dementia related to AF is thought to be a continuous disease 
rather than being dichotomous like stroke, OAC treatment may also be of 
value in individuals with lower CHA2DS2-VASc scores. 
More studies are required to answer these important questions regard-
ing who could benefit from OAC treatment. It would be interesting to 
perform a prospective study of micro-AF patients equipped with internal 
loop-recorders to determine the role of AF burden and timing in relation 
to stroke and dementia. In the future it would also be interesting to per-
form a trial using stroke as primary endpoint and major adverse event as 
secondary endpoints, randomising individuals with micro-AF and high 




Förmaksflimmer är den vanligaste hjärtrytmrubbningen av klinisk relevans. 
Eftersom förmaksflimmer förekommer i högre utsträckning hos äldre och 
befolkningen är åldrande beräknas sjukdomsprevalensen komma att öka. 
Livstidsrisken för att insjukna beräknas till 25 % för medelålders personer 
idag. Obehandlat förmaksflimmer innebär en kraftigt ökad risk för stroke 
hos de flesta individer. Strokeinsjuknanden som orsakas av förmaksflim-
mer är förknippade med högre mortalitet och morbiditet än stroke på grund 
av andra orsaker. Blodförtunnande behandling är indicerad för de flesta 
patienterna med förmaksflimmer och minskar risken för insjuknande i 
stroke med nästan 70 %. En tredjedel av patienterna med förmaksflimmer 
har inga symtom och en fjärdedel har endast intermittenta arytmiepisoder. 
De har trots detta en lika hög risk för insjuknande i stroke. 
Eftersom diagnosen förmaksflimmer kräver EKG görs ofta längre EKG-
registreringar för att leta efter förmaksflimmer och i flera studier används 
systematisk screening för förmaksflimmer. Ett exempel på en systematisk 
mass-screeningstudie för förmaksflimmer är STROKESTOP I, där 75- och 
76-åringar i Stockholms- och Hallands län screenades för förmaksflimmer 
med hjälp av intermittent EKG 30 sekunder två gånger dagligen i två veckor. 
Senare har även STROKESTOP II-studien genomförts. Genomförandet lik-
nar genomförandet i STROKESTOP I. Däremot inkluderades endast delta-
gare från Stockholms län och endast individer med NT-proBNP ≥125 ng/L 
fick genomgå extensiv förmaksflimmerscreening. Deltagarna instruerades 
att göra 30 sekunders intermittent EKG-registrering fyra gånger dagligen 
istället för två gånger dagligen, i två veckor.
För att en episod av oregelbunden hjärtrytm ska räknas som förmaksflim-
mer ska den enligt konsensus vara minst 30 sekunder lång. I samband 
med längre EKG-registreringar och systematisk screening för förmaksflim-
mer ses ofta kortare hjärtrytmrubbningar, ihållande förmaksarytmier och 
enstaka förmaksutlöst extraslag. Dessa har i registerstudier visats vara 
förknippade med en ökad risk för förmaksflimmer och även en ökad risk 
för stroke. I klinisk praxis anses korta episoder av förmaksflimmerliknande 
aktivitet fortfarande oftast som ofarliga. Patienter med dessa arytmier erb-
juds för närvarande ingen uppföljning eller behandling, trots att de har en 
ökad risk för både förmaksflimmer och stroke.
Förmaksarytmier kan ha olika karakteristika och anses vara förknippade 
med olika risker. I denna avhandling har vi främst fokuserat på riskerna 
och kliniska implikationer vid ihållande förmaksarytmier som liknar för-
maksflimmer, men som är kortare 30 sekunder och därmed ej uppfyller 
diagnoskriterierna för förmaksflimmer. Dessa episoder benämner vi mik-
roflimmer. I studie I definieras mikroflimmer som episoder av ≥4 efterföl-
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jande förmaksutlösta extraslag, oregelbunden rytm, avsaknad av p-vågor 
och med duration <30 sekunder. I studie II-IV definieras mikroflimmer 
som episoder av ≥5 efterföljande förmaksutlösta extraslag, hjärtfrekvens 
>100 slag/minut, oregelbunden rytm, avsaknad av p-vågor och med dura-
tion <30 sekunder. Det finns många olika utrustningar som används för 
förlängda EKG-registreringar. I våra studier har vi använt tum-EKG från 
Zenicor som intermittent EKG och R-test 4 från Novacor för kontinuerlig 
event-recording.
11.2 Syfte
I pilot-studien, studie I, var syftet att undersöka om mikroflimmer utgör en 
risk för senare utvecklande av förmaksflimmer genom upprepad screen-
ing. Vi ville även jämföra förmaksflimmerdetektionen mellan kontinuerlig 
event-recording och intermittent EKG. Syftet med studie II var att under-
söka om mikroflimmer kan användas som en indikator för oupptäckt 
förmaksflimmer, genom utvidgad screening. Studie III syftade till att i ett 
större material än i studie I, jämföra förmaksflimmerdetektionen mellan 
kontinuerlig event-recording och intermittent EKG i en äldre population, 
men även jämföra följsamhet i utredning och användarvänlighet hos EKG-
utrustningarna. I den sista studien, studie IV, ville vi ta reda på förekom-
sten och betydelsen av olika förmaksutlösta arytmier i en äldre population. 
Vi ville även jämföra hur stor andel av deltagarna med respektive arytmi 
som senare fick kliniskt diagnostiserat förmaksflimmer eller drabbades 
av stroke, samt deras mortalitet via registeruppföljning. 
11.3 Metod och Resultat
I studie I inkluderades, n=102, deltagare från en subpopulation i STROKESTOP 
I-studien. Deltagarna delades in i två grupper beroende på resultatet från 
deras intermittenta EKG-registreringar i STROKESTOP I: en mikroflim-
mergrupp, n= 54, och en matchad kontrollgrupp, n=48. Efter två års 
uppföljningstid bjöds deltagarna som inte kliniskt diagnosticerats med för-
maksflimmer in till upprepad förmaksflimmerscreening under två veckors 
tid. De screenades med en kontinuerlig event-recorder och intermittent EKG 
parallellt i två veckor. Efter en median-uppföljningstid på 2,3 år visades 
sig 50 % av deltagarna med mikroflimmer ha utvecklat förmaksflimmer 
jämfört med 10 % i kontrollgruppen, p <0,001. Av de nydiagnostiserade 
fallen med förmaksflimmer hittades 40 % (n=10/25) med intermittent EKG 
jämfört med 100 % (n=25/25) med kontinuerlig event-recording, p <0,001.
I studie II inbjöds deltagare från STROKESTOP II-studien där intermit-
tent EKG visat mikroflimmer, snarast möjligt efter sitt deltagande, till 
utvidgad förmaksflimmerscreening med kontinuerlig event-recorder i två 
veckor. En kontrollgrupp i STROKESTOP II-studien utan mikroflimmer 
screenades med båda EKG-metoderna parallellt. Av de 3763 deltagarna 
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i STROKESTOP II-studien, med förhöjt NT-proBNP och utan tidigare 
förmaksflimmerdiagnos, hade 225 (6%) mikroflimmer. Av dessa var 200 
villiga att delta i utvidgad screening med kontinuerlig event-recorder. 
Förmaksflimmer hittades hos 13 % i mikroflimmergruppen jämfört med 
3 % i kontrollgruppen, p <0,001.
Studie III utgår från kontrollgruppen i studie II. Alla deltagare i kon-
trollgruppen var vid studiestart fria från känd förmaksflimmerdiagnos och 
screenades för förmaksflimmer med hjälp av två olika EKG-utrustningar. 
De instruerades att registrera intermittent EKG 30 sekunder fyra gånger 
dagligen i två veckor samt att bära kontinuerlig event-recorder parallellt. 
Båda utrustningarna kunde manuellt aktiveras för EKG-inspelning vid 
symtom. Deltagarna ombads även att fylla i ett formulär med jämförande 
frågor gällande följsamhet till undersökning och användarvänlighet, för de 
två EKG-utrustningarna. Intermittent EKG diagnosticerade förmaksflimmer 
hos 2 % (n=5/269) och kontinuelig event-recording hittade förmaksflimmer 
hos 6 % (n=15/269), p = 0,002. Ingen deltagare diagnosticerades enbart 
med intermittent EKG. På en skala mellan 1 och 5, där 1 motsvarade 
väldigt lätt att använda, graderades användarvänligheten för intermittent 
EKG enligt följande 1 (interquartile range [IQR]: 1–1) och för kontinuerlig 
event-recording till 2 (IQR: 1–3), p <0,001.
Mikroflimmer eftersöktes bara hos deltagare under sista månaderna av 
inklusion i STROKESTOP I, därför ingår endast en liten andel av deltagarna 
med mikroflimmer i studie I. En datoriserad algoritm användes i studie 
IV för att hitta fler deltagare med förmaksarytmier i STROKESTOP I. Alla 
episoder som identifierades av algoritmen granskades även manuellt. Det 
primära utfallsmåttet var kliniskt diagnostiserat förmaksflimmer (register-
diagnos), sekundära utfallsmått var stroke och död. Uppföljningstiden var 
4,2 (IQR: 3,8–4,4) år. Av de 6100 deltagarna hade 15 % förmaksarytmier 
av betydelse. Deltagarna med arytmier delades in i grupper beroende på 
typ av förmaksarytmi. Ihållande förmaksarytmier visade sig vara starkare 
associerade med förmaksflimmer än enskilda extraslag. Deltagarna med 
mikroflimmer, n= 97 (1,6 %) hade betydligt högre risk för förmaksflimmer 
(hazard ratio 4,3; 95 % konfidens intervall 2,7–6,8) än personer med andra 
typer av ihållande hjärtklappningar. De hade också en ökad risk för död 
(hazard ratio 2,0; 95 % konfidens intervall 1,1–3,8). 
11.4 Slutsatser
Förekomsten av kliniskt signifikanta förmaksarytmier i åldersgruppen 
75–76 år är ungefär 15 % och förekomsten av mikroflimmer är minst 1,6–6 
%. Det finns flera olika typer av ihållande förmaksarytmier, av dessa är 
mikroflimmer, som i sin elektriska aktivitet är mest likt förmaksflimmer 
också starkast associerat med förmaksflimmer. 
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Mikroflimmer tycks kunna vara både en markör för att odiagnostiserat 
förmaksflimmer kan finnas, men även ett förstadium till förmaksflimmer. 
Med kort uppföljningstid (3 månader) till utvidgad förmaksflimmerscreening 
diagnosticerades 13 % av deltagare med mikroflimmer med förmaksflim-
mer, jämfört med 50 % efter 2 år. Äldre individer med mikroflimmer har 
också en ökad risk för död. 
Betydligt färre fall av förmaksflimmer diagnostiseras kliniskt hos personer 
med mikroflimmer jämfört med vid upprepad screening i denna högrisk-
grupp. Kontinuerlig event-recording hittar tre gånger så många nya fall 
av förmaksflimmer som intermittent EKG i en äldre population, även om 
följsamheten och användarvänligheten skattas högre för intermittent EKG. 
Utvidgad och upprepad förmaksflimmerscreening med kontinuerligt EKG 
är att rekommendera hos individer med mikroflimmer för att tidigt diag-
nosticera förmaksflimmer och därmed sannolikt minska risken för stroke.
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